Retrophin Inc (NASDAQ:RTRX)‘s stock had its “outperform” rating reissued by analysts at William Blair in a research report issued on Thursday.
Several other research firms have also recently weighed in on RTRX. BMO Capital Markets set a $46.00 target price on Retrophin and gave the stock a “buy” rating in a research note on Wednesday, December 14th. Zacks Investment Research upgraded Retrophin from a “hold” rating to a “strong-buy” rating and set a $24.00 target price for the company in a research note on Tuesday, March 7th. Finally, JMP Securities set a $28.00 target price on Retrophin and gave the stock a “buy” rating in a research note on Thursday, December 15th. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $32.25.
Retrophin (NASDAQ:RTRX) traded down 0.37% during midday trading on Thursday, hitting $18.77. 88,475 shares of the stock traded hands. The firm’s 50-day moving average is $18.63 and its 200-day moving average is $19.84. Retrophin has a 52-week low of $13.31 and a 52-week high of $24.57. The company’s market cap is $715.01 million.
ILLEGAL ACTIVITY WARNING: “Retrophin Inc (RTRX) Stock Rating Reaffirmed by William Blair” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2017/04/21/retrophin-inc-rtrx-now-covered-by-analysts-at-william-blair-updated.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Gargoyle Investment Advisor L.L.C. purchased a new position in Retrophin during the third quarter valued at approximately $206,000. Highbridge Capital Management LLC purchased a new position in Retrophin during the fourth quarter valued at approximately $243,000. Monarch Partners Asset Management LLC purchased a new position in Retrophin during the third quarter valued at approximately $263,000. HBK Investments L P purchased a new position in Retrophin during the third quarter valued at approximately $291,000. Finally, Russell Investments Group Ltd. purchased a new position in Retrophin during the fourth quarter valued at approximately $387,000.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc and related companies with MarketBeat.com's FREE daily email newsletter.